

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/585,817
		Filing Date	June 1, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
Total Number of Pages in This Submission	8	Attorney Docket Number	015270-005910US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Request for Corrected Filing Receipt (3 pp.) w/attached copies of: Pages 1-2 of a Marked-Up Copy of the Filing Receipt mailed 10/13/00; 6/4/03 Supp. ADS (1 pg.); Page 2 of Amendment filed 6/4/03.
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>
Date	April 27, 2004

CERTIFICATE OF FACSIMILE TRANSMISSION			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Office of Initial Patent Examination, Fax No. 1-703-746-9195 on April 27, 2004.			
Typed or printed name	Rosemarie L. Celli		
Signature	<i>Rosemarie L. Celli</i>	Date	April 27, 2004

60203396 v1

I hereby certify that this correspondence is being facsimile transmitted to
facsimile number 1-703-746-9195, Attention OIPE/Customer Service on
April 27, 2004

By: _____


Rosemarie L. CelliPATENT

Attorney Docket No.: 015270-005910US
Client Ref. No.: 209-US-NEW6

Application No.: 09/585,817
Applicant: Dale B. Schenk
Filed: June 1, 2000
TC/A.U.: 1600/1647
Examiner: Christopher J. Nichols

Confirmation No.: 4693

Docket No.: 015270-005910US
Customer No.: 20350

Office of Initial Patent Examination
United States Patent and Trademark Office

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Issuance of a corrected filing receipt is respectfully requested. Attached hereto is
a marked-up copy of the Filing Receipt mailed by the Patent Office on October 13, 2000.

Please correct the GRP ART UNIT information; delete "1646" and replace it
with "1647".

Please correct the ATTY.DOCKET.NO information; delete "209-US-NEW6"
and replace it with "015270-005910US".

Application No. 09/724,570
Request for Corrected Filing Receipt of April 27, 2004

PATENT

Please correct the correspondence address information.

Delete:

Elan Pharmaceuticals Inc
Intellectual Property Department
800 Gateway Boulevard
South San Francisco, CA 94080

and replace it with:

TOWNSEND AND TOWNSEND AND CREW LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

Please correct the Domestic Priority data as claimed by applicant. (See A copy of the Supplemental Application Data Sheet and page 2 of the amendment filed on June 4, 2003, attached hereto.)

Replace to existing domestic priority data with:


THIS APPLICATION CLAIMS BENEFIT OF 60/137,010 06/01/1999
THIS APPLICATION IS A CIP OF 09/580,015 05/26/2000
WHICH IS A CIP OF 09/322,289 05/28/1999
WHICH IS A CIP OF 09/201,430 11/30/1998
WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998
AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

Application No. 09/724,570
Request for Corrected Filing Receipt of April 27, 2004

PATENT

Applicant believes no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the previously noted deposit account.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC
60110444 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/585,817	06/01/2000	1646 1647	2442	00200-US NEWS 015270005910	16	57	5

~~24035~~
~~ELAN PHARMACEUTICALS, INC.~~
~~INTELLECTUAL PROPERTY DEPARTMENT~~
~~800 GATEWAY BOULEVARD~~
~~SOUTH SAN FRANCISCO, CA 94080~~

FILING RECEIPT



OC000000005470721

OCT 27 2000

20350
 TOWNSEND AND TOWNSEND AND CREW, LLP
 TWO EMBARCADERO CENTER
 EIGHTH FLOOR
 SAN FRANCISCO, CA 94111-3834

Date Mailed: 10/13/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dale B. Schenk, Burlingame, CA :

Continuing Data as Claimed by Applicant

~~THIS APPLN CLAIMS BENEFIT OF 60/437,010 06/01/1999~~

Foreign Applications

THIS APPLICATION CLAIMS BENEFIT OF 60/137,010 06/01/1999
 THIS APPLICATION IS A CIP OF 09/580,015 05/26/2000
 WHICH IS A CIP OF 09/322,289 05/28/1999
 WHICH IS A CIP OF 09/201,430 11/30/1998
 WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998
 AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

If Required, Foreign Filing License Granted 08/15/2000

Title

Prevention and treatment of amyloidogenic disease

Preliminary Class

514

Data entry by : ZIMMERMAN, SHAUNA

Team : OIPE

Date: 10/13/2000

A JUDICIAL NOTICE OF THE UNITED STATES PATENT AND TRADEMARK OFFICE IS HEREBY GIVEN THAT THE ABOVE INFORMATION IS A PUBLIC NOTICE OF THE INFORMATION CONTAINED HEREIN IS NOT TO BE USED FOR ANY OTHER PURPOSE THAN THAT FOR WHICH IT WAS SUBMITTED.

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Appl. No. 09/585,817
Amdt. dated June 4, 2003
Reply to Office Action of December 4, 2002

PATENT

Amendments to the Specification:

At page 1, please delete the existing cross-reference to related applications and replace with the following replacement paragraph.

This application claims the benefit under 35 U.S.C. 119(e) of U.S. Application No. 60/137,010, filed June 1, 1999, which is hereby incorporated herein in its entirety. This application is also a continuation-in-part of U.S. Application No. 09/580,015, filed May 26, 2000, which is a continuation-in-part of U.S. Application No. 09/322,289, filed May 28, 1999, which is a continuation in part of U.S. 09/201,430, filed November 30, 1998, which claims the benefit under 35 U.S.C. 119(e) of U.S. Application No. 60/080,970, filed April 7, 1998, and U.S. Application 60/067,740, filed December 2, 1997.

Please replace the paragraph beginning on page 10, line 26 of the specification with the following replacement paragraphs.

Figs. 15A-E: A β levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A β level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

Fig. 15A: The values for mice for the PBS-treated control group and the untreated control group.

Fig. 15B: The values for mice in the AN1528/alum and AN1528/MPL-treatment groups.

Fig. 15C: The values for mice in the AN1528/QS21 and AN1792/Freund's adjuvant treatment groups.

Fig. 15D: The values for mice in the AN1792/Thimerosal and AN1792/alum treatment groups.